A Retrospective Cohort Study of Healthcare Utilization Associated with Paravertebral Blocks for Chronic Pain Management in Ontario

George Deng\textsuperscript{a}, Michael Gofeld\textsuperscript{b}, Jennifer N Reid\textsuperscript{e}, Blayne Well\textsuperscript{c,d}, Anne MR Agur\textsuperscript{d}, and Eldon Loh\textsuperscript{f,g}

\textsuperscript{a}Vivo Cura Health, Calgary, Alberta, Canada; \textsuperscript{b}Silver Pain Care, Toronto, Ontario, Canada; \textsuperscript{c}ICES, Ontario, Canada; \textsuperscript{d}Department of Surgery, Western University, London, Ontario, Canada; \textsuperscript{e}Division of Anatomy, Department of Surgery, University of Toronto, Toronto, Ontario, Canada; \textsuperscript{f}Department of Physical Medicine and Rehabilitation, Western University, London, Ontario, Canada; \textsuperscript{g}Parkwood Institute Research, Lawson Health Research Institute, London, Ontario, Canada

\textbf{ABSTRACT}

\textbf{Background:} Injections, particularly paravertebral blocks (PVBs), are frequently performed procedures in Ontario, Canada, for the management of chronic pain, despite limited evidence and risk of complications.

\textbf{Aim:} This study examines usage patterns of PVBs to evaluate their effects on healthcare utilization and opioid prescribing.

\textbf{Methods:} A retrospective cohort study in Ontario using administrative data. Ontario residents receiving their initial PVBs between July 1, 2013 and March 31, 2018 were included. Changes in use of other interventions, physician visits, and opioids were compared to the 12-month periods before and after index PVBs. Data use was authorized under section 45 of Ontario’s Personal Health Information Protection Act.

\textbf{Results:} 47,723 patients received their initial PVBs in the study period. The rate of index PVBs increased from 1.61 per 10,000 population (2013) to 2.26 per 10,000 (2018). Initial PVBs were performed most commonly by family physicians ($N = 25,042$), followed by anesthesiologists ($N = 14,195$). 23,386 patients (49%) received 1 to 9 repeat PVBs in the 12 months after index PVB; 12,474 patients (26.15%) received 10 or more. Use of other nonimage guided interventional pain procedures per patient (mean±SD) increased from 2.19 ± 9.35 to 31.68 ± 52.26 in the year before and after index PVB. Relevant physician visits per patient (mean±SD) also increased from 2.92 ± 3.61 to 9.64 ± 11.77. Mean opioid dosing did not change significantly between the year before and the year after index PVB.

\textbf{Conclusion:} PVBs are associated with increases in healthcare utilization and no change in opioid use patterns.

\textbf{RÉSUMÉ}

\textbf{Contexte:} Les injections, en particulier les blocs paravertébraux (BPV), sont des procédures fréquemment effectuées en Ontario, Canada, pour la prise en charge de la douleur chronique, malgré des données probantes limitées et le risque de complications.

\textbf{Objectif:} Cette étude examine les modes d’utilisation des BPV afin d’évaluer leurs effets sur l’utilisation des soins de santé et la prescription d’opioïdes.

\textbf{Méthodes:} Étude de cohorte rétrospective utilisant les données administratives en Ontario. Les résidents de l’Ontario ayant reçu leur BPV initial entre le 1er juillet 2013 et le 31 mars 2018 ont été inclus. Les changements dans l’utilisation des autres interventions, les visites aux médecins et les opioïdes ont été comparés 12 mois avant et 12 mois après le BPV de référence. L’utilisation des données a été autorisée en vertu de la Loi sur la protection des renseignements personnels sur la santé de l’Ontario.

\textbf{Résultats:} 47 723 patients ont reçu leur BPV initial au cours de la période étudiée. Le taux de BPV est passé de 1.61 pour 10 000 habitants (2013) à 2.26 pour 10 000 (2018). Les BPV de référence étaient effectués le plus souvent par des médecins de famille ($N = 25,042$), suivis par les anesthésistes ($N = 14,195$). 23 386 patients (49%) ont reçu de 1 à 9 BPV répétés dans les 12 mois suivant le BPV de référence; 12 474 patients (26.15 %) en ont reçu 10 ou plus. L’utilisation d’autres procédures interventionnelles pour la douleur non guidées par l’image par patient (moyenne ± ET) est passée de 2.19 ± 9.35 à 31.68 ± 52.26 l’année précédant et suivant le BPV. Les visites médicales pertinentes par patient (moyenne ± ET) ont également augmenté de 2.92 ± 3.61 à 9.64 ± 11.77. La dose moyenne d’opioïdes n’a pas changé de manière significative entre l’année précédant et suivant le BPV de référence.

\textbf{Conclusion:} Les BPV sont associés à une augmentation de l’utilisation des soins de santé et ne sont associés à aucun changement dans les modes d’utilisation des opioïdes.

\textbf{CONTACT} Eldon Loh \textsuperscript{e} eldon.loh@sjhc.london.on.ca St. Joseph’s Health Care London, Parkwood Institute (Main Building), P.O. Box 5777, STN B London ON, N6A 4V2

\textsuperscript{e} Supplemental data for this article can be accessed on the publisher’s website.

\textcopyright 2021 The Author(s). Published with license by Taylor & Francis Group, LLC.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
**Introduction**

“Nerve blocks” are a common, nonspecific term for chronic pain injection methods which involve instillation of local anesthetic (sometimes with the addition of corticosteroids) to temporarily interrupt the transmission of sensory information. They are a frequently performed procedure in Ontario pain clinics. A recent Toronto Star report has questioned the appropriateness of these blocks, highlighting a high frequency of injections, significant physician billings, and a lack of peer-reviewed evidence of efficacy. In 2012, the Ontario government unilaterally reduced reimbursement for paravertebral nerve blocks (PVBs), which represent a significant proportion of these injections. PVBs involve the infiltration of local anesthetic into the paravertebral compartment to temporarily anesthetize nearby neural structures (Fig. 1). In the pain literature, PVBs have only been evaluated in the context of acute trauma, cancer pain and perioperative regional anesthesia.

Landmark techniques (compared to image-guided techniques) for PVBs have been shown to be unpredictable, with spread beyond the paravertebral space in 82% of cases and the potential for significant complications. Given the risks of PVBs, as well as the specific indications for these procedures, there is no obvious explanation accounting for the high prevalence of OHIP billings for PVBs. Despite criticism voiced by professional societies, some clinicians advocate for the effectiveness of PVBs, reporting pain reduction ≥50% in more than 70% of cases. Additionally, there are anecdotal patient reports that these injections are a better alternative to opioid use, and reduce healthcare utilization.

The overall goal of this study is to assist healthcare providers and policy makers refine the appropriate use of PVB from a resource stewardship perspective, and to improve resource allocation for chronic pain management in Canada. By using a similar population-level methodology employed in our previous study evaluating the effectiveness of radiofrequency ablation in Ontario, the objectives of this retrospective cohort study were to: (1) explore the patient and healthcare utilization characteristics associated with the use of PVBs in Ontario, and (2) to evaluate the impact of PVBs on healthcare utilization and opioid use in patients with chronic pain receiving these interventions in Ontario.

**Methods**

**Design and Setting**

A retrospective cohort study was conducted using administrative data from the province of Ontario, Canada. The study included residents of Ontario who received their initial PVB between July 1, 2013 and March 31, 2018. Since the Narcotics Monitoring System was not available until 2013, that is when the study period began. The end date was chosen to allow a sufficient follow-up period to evaluate outcomes. Data use in this project was authorized under section 45 of Ontario’s Personal Health Information Protection Act, which does not require review by a Research Ethics Board. Individual patient consent was not required.

**Data Sources**

Several linked administrative data sources were used for this study, including: (1) Narcotics Monitoring System (NMS, containing all opioids dispensed in the province); (2) Canadian Institute for Health Information Discharge Abstract Database/Same Day Surgery (CIHI-DAD/SDS, identifying all hospital admissions and procedures); (3) National Ambulatory Care Reporting System (NACRS, identifying all emergency room encounters); (4) Ontario Health Insurance Plan (OHIP, containing all physician billing codes for patient assessment or treatment); (5) ICES physician database alongside (6) Corporate provider database (IPDB, CPDB; identifying physician specialty and years of practice); (7) Registered Persons...
database (RPDB, containing vital statistics and patient demographics); (8) Patient Contact and Eligibility Yearly Files (CONTACT, identifying prior patient healthcare contact information); and (9) Ontario Population Estimates and Projections, distributed by the Ontario Ministry of Health and Long-Term Care: IntelliHEALTH Ontario (POP, used to calculate rates of PVB procedures over time). Data was analyzed at ICES Western using unique, encoded personal identifiers to link datasets. The validity of the data elements in the above databases has been previously documented.21–25

**Patient Population**

Patients with PVB performed between July 1, 2013 and March 31, 2018 were identified by the unique physician OHIP billing codes G228 (billing for the first PVB) and G123 (billing for subsequent PVB on the same clinical encounter). The first occurrence of the PVB OHIP billing code was considered the index date.

Exclusion criteria for the main cohort included: PVB in the 5 years prior to the index date (to ensure index treatments were identified), no healthcare contact between 3 to 5 years prior to the index date (to ensure patients would have a minimum 2-year administrative data history), nonresidents of Ontario, patients who died or emigrated from the province during the 1-year period after the index date, and PVBs done on Emergency room visits.

**Outcomes**

The primary outcome was the change in healthcare and opioid utilization in the immediate 12-month periods before and after the index date. Healthcare utilization was assessed through changes in (1) overall physician visits, (2) physician visits in Family Medicine, Physical Medicine and Rehabilitation (PMR), Orthopedics, Neurology, Neurosurgery, or Anesthesiology, and (3) the use of interventional pain procedures other than PVB. Utilization characteristics of image-guided procedures, versus those that do not require imaging, were also evaluated. Image-guided interventional procedures were defined as those procedures whose OHIP codes require the use and documentation of image-guidance to submit a billing. These codes included fluoroscopic-guided cervical/thoracic/lumbar facet intra-articular injection/medial branch blocks, ultrasound-guided lumbar medial branch blocks, fluoroscopic-guided sacroiliac joint injections, fluoroscopic stellate ganglion blocks, and nerve root injections. Opioid utilization was assessed by comparing (1) total daily oral morphine equivalent (MEQ) dosing, and (2) total number of opioid prescriptions, in the year before and after the index date.

Secondary outcomes were the number of each specialty billing for these injections, the proportion of people who received multiple PVBs in a year, the average number of PVBs per person performed in a year, the average time between subsequent PVBs, and the number of levels billed per PVB. The number of emergency room visits, and imaging requirements (e.g., CT/MRI), in the 2 week period post-procedure was used to estimate adverse events associated with PVBs.

**Statistical Analysis**

Differences between pre-post PVB groups was tested using a Wilcoxon signed-rank test. In all pre-post group comparisons, a two-sided p-value <0.05 was considered significant. A test for trend on the rate of index PVB procedures between July 1, 2013 and March 31, 2018 was carried out using linear regression, where a two-sided p-value <0.05 was considered significant. In SAS, PROC REG was used, and model assumptions of homoscedasticity and normally distributed residuals were confirmed graphically. Additionally, no multicollinearity was confirmed using VIF, and Cook’s D statistic ensured no unusual outliers. Descriptive statistics were used to describe distributions of the pre-post PVB groups. All analyses were conducted using SAS version 9.4 (SAS Institute, Cary, NC). In accordance with ICES privacy policies, cell sizes less than or equal to five cannot be reported.

**Results**

A total of 47,723 patients between July 1, 2013 and March 31, 2018 met inclusion criteria (Fig. 2). 60.42% were female (N = 28,832) and mean age was 51.34 years (standard deviation (SD) ± 15.72 years). On a per capita basis, using the POP dataset, the rate of index PVBs increased from 1.61 per 10000 population in the first study period (third quarter of 2013) to 2.26 per 10000 in the final study period (first quarter of 2018) (p < .0001).

On the index date, 11.99% (N = 5,720) had 1 PVB level billed, and 87.99% (N = 41,992) had 2 levels billed (mean ± SD; 1.88 ± 0.33). PVBs were most prevalently performed by family physicians (52.47%) followed by anesthesiologists (29.74%) (Table 1).

On the day of the index PVB, 85.43% (N = 40,768) of all patients received at least one additional injection (mean ± SD; 2.42 ± 1.58 additional injections). The most commonly billed additional injection on the index date was trigger point injection (Table 2). A total of 1,606 patients (3.37%) visited an emergency room within the first 14 days post-PVB and a total of 992 patients (2.08%) had a CT and/or MRI within the first 14 days post-procedure.
Healthcare Utilization before and after Index Date

PVB and Other Interventional Procedures

In the year following the index PVB, 49% of patients received between 1 and 9 repeat PVBs, 26.15% of patients received 10 or more repeat PVBs and 24.86% did not have follow-up PVB. 7.77% of the sample (N = 3,706) received 30 or more repeat PVBs during the year (supplemental material, Appendix 1). The average (± SD) number of days between subsequent PVBs was 32.38 ± 44.66.

Table 1. Number of index PVBs performed by specialty in Ontario, Canada.

| Specialty           | Index PVB, N(%) patients |
|---------------------|--------------------------|
| Family Medicine     | 25,042 (52.47%)          |
| Anesthesiology      | 14,195 (29.74%)          |
| Radiology           | 2,280 (4.78%)            |
| ER                  | 1,743 (3.65%)            |
| PMR                 | 1,352 (2.83%)            |
| Orthopedic          | 1,172 (2.46%)            |
| Neurosurgery        | 1,034 (2.17%)            |
| Other               | 779 (1.63%)              |
| Neurology           | 126 (0.26%)              |

Table 2. The most common procedures/nerve blocks performed on the same day as the index PVB and the number/proportion of patients receiving each procedure listed in descending order.

| Types of Procedure/Nerve Block Performed on Same Day as Index PVB | Number (%) of Patients |
|---------------------------------------------------------------------|------------------------|
| Trigger point                                                       | 25,821 (54.11%)        |
| Injection of bursa, or injection/aspiration of joint, ganglion, or tendon sheath | 25,380 (53.18%)        |
| Scapular nerve                                                      | 14,227 (29.81%)        |
| Other cranial nerves                                               | 13,171 (27.60%)        |
| Sciatic                                                            | 11,727 (24.57%)        |
Table 3. The five most common interventional procedures (other than PVB and certain specific image-guided procedures) performed in the year after the index PVB. This comparison is done on a subgroup of patients who had at least one interventional procedure prior to index PVB. *indicates a statistically significant change \((p < .0001)\) from the year before to the year after.

| Type of Procedure Performed | Procedures Performed in Pre-Period (N, total procedures) | Procedures Performed in Post-Period (N, total procedures) |
|-----------------------------|--------------------------------------------------------|----------------------------------------------------------|
| Injection of bursa, or injection/aspiration of joint, ganglion, or tendon sheath | 20,019 | 71,035* |
| Trigger point | 17,585 | 46,877* |
| Scapular nerve | 9,700 | 31,389* |
| Other cranial nerves | 8,461 | 28,192* |
| Intramuscular, subcutaneous or transdermal injection | 16,539 | 12,659* |

in the pre-period to 308,541 in the post-period \((p < .0001)\) (Table 4). The greatest increase related to family medicine visits. The post-period increase in visits relates primarily to PVB injections; when these visits are excluded there is only a slight post-period increase in total physician visits (Table 4). There was a reduction of visits to orthopedic, neurology, and physical medicine and rehabilitation specialists and a small increase in visits to neurosurgery (Table 4).

Opioid Utilization

A total of 33,821 patients met the inclusion criteria for this analysis (Fig. 2). In the year before and after the index PVB, the mean MEQ ± SD was 13.01 ± 32.03 mg and 13.17 ± 30.61 mg respectively. Overall, 43% had an increase, 17% had no change, and 40% had a decrease in MEQ dosing post-PVB \((p = .095)\) (Fig. 3).

There were 28,807 patients who received an opioid prescription in the year prior to their index PVB. Of those patients, 7,007 patients did not receive any opioid prescriptions in the year after the index PVB. The majority of those who did not require opioid prescriptions in the post-period had only 1 prescription in the pre-index PVB period (Table 5).

Discussion

Significant healthcare and societal resources are dedicated to chronic pain management, and consequences of untreated pain are dire.\(^{27–29}\) The results of this study raise concerns regarding use of PVBs. First, PVBs are frequently billed once treatment is initiated. Second, PVBs are associated with increases in healthcare utilization, as measured by physician visits and other interventions. Third, there is minimal change in opioid utilization post-treatment.

Healthcare Utilization – Interventional Procedures

Many patients in this study received multiple concurrent injections after PVB was initiated. Although patients may report anecdotal benefit from this combined treatment regimen, the evidence that these procedures provide significant pain relief is limited.\(^{30–33,34,35}\)

The need for multiple different regional procedures suggests that these patients have fairly diffuse pain. Central sensitization and psychosocial factors may better account for this type of pain; the ability of multiple injections to provide meaningful relief in this scenario is questionable. Alternative hypotheses for benefit include placebo response, positive therapeutic alliance from frequent visits, and provider expectations.

The paucity of image-guided procedures performed in this cohort may reflect the need for specialized equipment and training, and better-defined selection criteria for these procedures. Interestingly, there was a significant decrease in the number of neuraxial interventional procedures following index PVB (Appendix 3), whereas there was a 3.5 fold increase in injection of bursa, or injection/aspiration of joint, ganglion, or tendon sheath; trigger point injection; scapular nerve block; and other cranial nerves block (Table 3). This drastic change in management approach after

Table 4. Total physician visits and mean physician visits with standard deviation (SD) per patient by specialty before and after index PVB, including and excluding visits related to PVB. PVB, paravertebral block. The comparison of total physician visits is done on a subgroup of patients who had at least one physician visit prior to index PVB. *indicates a statistically significant change \((p < .0001)\).

|                        | Total Physician Visits | Total Visits per Patient | Total Visits per Patient Excluding PVB |
|------------------------|------------------------|--------------------------|----------------------------------------|
|                        | Pre-Period (N, total visits) | Post-Period (N, total visits) | Pre-Period (Mean ± SD) | Post-Period (Mean ± SD) | Pre-Period (Mean ± SD) | Post-Period (Mean ± SD) |
| Total number of relevant physician visits | 139,559 | 308,541* | 2.92 ± 3.61 | 9.64 ± 11.77 | 2.92 ± 3.61 | 3.71 ± 5.28 |
| Family Medicine visits | 62,507 | 212,214* | 1.31 ± 2.65 | 6.06 ± 11.01 | 1.31 ± 2.65 | 1.82 ± 4.36 |
| Orthopedics visits | 25,749 | 20,048* | 0.54 ± 1.34 | 0.72 ± 2.44 | 0.54 ± 1.34 | 0.52 ± 1.35 |
| Anesthesia visits | 22,997 | 54,990* | 0.48 ± 1.47 | 1.95 ± 4.72 | 0.48 ± 1.47 | 0.82 ± 2.31 |
| Neurology visits | 13,951 | 6,879* | 0.29 ± 0.85 | 0.27 ± 0.89 | 0.29 ± 0.85 | 0.25 ± 0.79 |
| Physical Medicine and Rehabilitation visits | 10,044 | 5,695* | 0.21 ± 0.80 | 0.25 ± 1.09 | 0.21 ± 0.80 | 0.20 ± 0.83 |
| Neurosurgery visits | 4,311 | 8,715* | 0.09 ± 0.56 | 0.39 ± 3.07 | 0.09 ± 0.56 | 0.10 ± 0.62 |
initiation of PVB is unusual, as pain symptoms and signs are not expected to significantly change following PVB. The question arises as to whether the change in procedural billing patterns post-index PVB is driven by other factors, including financial considerations.

**Healthcare Utilization – Physician Visits**

Family physicians had the highest increase in physician visits post-index PVB, followed by anesthetists. The increase in visits post-PVB was driven mainly by repeated PVB injections, as physician visits only slightly increased when PVB visits were excluded. The high incidence of family physician PVB billings is unexpected, as indications for PVB are highly specific and would likely be outside the scope of practice for most family physicians.

One possible explanation for the high frequency of these billings is that other nonimage guided interventional procedures (e.g., trigger point injections) are being misclassified as PVBs. For example, a physician may bill insertion of needles into the paraspinal musculature (e.g., multifidus, erector spinae) as a PVB, although a trigger point injection may be a more accurate description. Even within the literature, "paravertebral injection" has been used to describe procedures such as facet joint injections and/or medial branch blocks. It is possible that PVB and other non-image guided interventional codes in Ontario may be used in place of more appropriate billing codes that are less remunerative or have more restrictive conditions on their use.

The high number of procedures performed suggests that this is not an issue involving a small group of physicians but a wider systemic issue. The collective billing of PVB and associated interventional procedures have totaled over 420 million CAD since 2011, with physicians billing multiple millions per year for these injections. Although a discussion on billing and resource stewardship ethics is beyond the scope of this article, the study team notes that allocating funds to PVB and associated procedures may decrease access to other options for pain management, and may affect the availability of healthcare resources generally (i.e., nonpain management resources). Ongoing education on appropriate indications for pain interventions may improve not only healthcare utilization but also patient outcomes.

The study team notes that there is a reduction in visits to some specialties following initiation of PVBs, specifically orthopedics, PMR, and neurology. There may be
several reasons for this decrease, but improvement in patient symptoms that negates the need to involve these specialties cannot be excluded.

**Opioid Utilization**

A proportion of those who received opioid prescriptions in the year prior to PVB did not require one in the year after. However, most of these patients only had one prescription in the year pre-procedure. Thus, their opioid use may not have been high to begin with, or may have been incidental and not related to the indication for PVB. In contrast, the majority of those who received five or more prescriptions in the year before PVB continued to receive a similar number of prescriptions in the year following. Mean opioid dose did not significantly change in the year before and after index PVB; the overall effect of PVB and associated interventions on opioid utilization is uncertain.

**Comparison to Radiofrequency Ablation**

In Ontario, radiofrequency ablation (RFA) and its impact on healthcare utilization, using the same outcome measures, has also been assessed using population level data. Although a formal control group was not included in this paper, the results from the RFA paper can be useful in contrasting the outcomes of this paper. In contrast to PVB, the mean (± SD) time between repeat RFA was much longer (432.20 ± 375.28 days) compared to PVB (32.38 ± 44.66 days). Importantly, RFA significantly reduced healthcare utilization in the year post-procedure in terms of physician visits and repeat interventional procedures. Based on this data and the existing literature, there is still an important role for targeted interventions that are appropriately applied.

**Risks**

PVBs are associated with a number of potential risks, including vascular puncture, pneumothorax, pleural puncture, hematoma, signs of epidural or intradural spread, pain at injection site, symptomatic bradycardia and hypotension, vasovagal response, and local anesthetic toxicity. The authors note that ED visits and the need for imaging after PVB is similar to that after the Ontario RFA study (ED visits: 3.25% (RFA) vs. 3.37% (PVB); imaging studies: 1.68% (RFA) vs. 2.08% (PVB)), although the follow-up inclusion period for ED visits and imaging studies was longer in the RFA study (up to 4 weeks compared to only 2 weeks in this study). While emergency department visits and the need for further advanced imaging modalities was used as a surrogate to identify any potential risks, it cannot be assumed that these visits/imaging studies are necessarily related to the procedure themselves.

**Limitations**

A limitation of this study is that it is retrospective, and misclassification errors may occur within the provincial database. The exact indication for PVBs was unknown as the OHIP billing code does not discriminate between chronic pain versus other reasons for PVB, so it is possible that the high proportion of PVBs in Ontario is due to a reason other than chronic pain. However, the authors find it less likely that the large proportion of PVBs in Ontario relate to nonchronic pain indications for two reasons. First, specific indications for PVBs in the literature (e.g., acute trauma, cancer pain and perioperative regional anesthesia) imply time-limited treatments in highly specialized environments. However, we found that the majority of billing instances of these procedures involve more generalized practitioners (e.g., Family Medicine) and occur recurrently over a prolonged period of time. Second, we excluded all patients who had a NACRS visit on the same day as their index PVB (n = 1318). NACRS includes all emergency department visits, which the authors reasoned would help to eliminate those receiving PVBs for other reasons (e.g., trauma).

Another major limitation of the study was a lack of a formal control group. The study team was able to make comparisons to a previous study on RFA in Ontario, which utilized a similar methodology and assessed similar outcomes. However, the current study did not specifically include a control group where no interventional pain procedures were provided, which could affect interpretation of the findings. We note that it would be difficult to identify such a control group because there are no specific pain assessment OHIP billing codes available; OHIP billing codes are specialty provider specific (with no specific codes within Pain Medicine outside of procedural codes).

The outcome measures that can be assessed are limited as a result of the use of an administrative database. Changes in outcomes such as pain, sleep, function, and mood are not quantifiable given the nature of the data collected within the available databases. Other measures not available within administrative databases include allied health access and changes in employment status (i.e., return to work). Additionally, we did not quantify the use of over the counter medications, illicit drug use, cannabis, and pain modulating antidepressants and antiepileptics.
Data was interpreted using PVBs as the index procedure due to its high yearly cumulative billing. However, the authors suspect that using another nonimage guided interventional procedure as the index would yield similar findings.

Conclusions regarding opioids were more difficult to interpret as there have been efforts to reduce opioid prescription in chronic pain patients during the study period.

**Conclusion**

PVBs for pain management were associated with increased total physician visits, increased use of other nonimage-guided interventional procedures, and uncertain effects on opioid utilization. A broader discussion on the ongoing, prevalent use of this modality for chronic pain management, particularly given a lack of evidence in the literature assessing its effectiveness, should be considered.

**Acknowledgement**

The authors wish to thank Dr. Sarvenaz Parish for illustrating the image in Figure 1.

**Disclosure Statement**

GD and MG practice in community pain clinics. GD, MG, and EL practice pain medicine with interventional pain management as part of their skillset, although none of the authors perform PVBs. GD received funding from an Earl Russell trainee grant for this work. JNR, BW, and AMRA do not declare any conflicts of interest.

**Funding**

This study was supported by ICES, which is funded by an annual grant from the Ontario Ministry of Health and Long-Term Care (MOHLTC). The study was completed at the ICES Western site, where core funding is provided by the Academic Medical Organization of Southwestern Ontario, the Schulich School of Medicine and Dentistry, Western University, and the Lawson Health Research Institute. GD received funding for this study from an Earl Russell Trainee Grant. Parts of this material are based on data and/or information compiled and provided by Canadian Institute for Health Information (CIHI). However, the analyses, conclusions, opinions and statements expressed in the material are those of the author(s), and not necessarily those of CIHI.

**ORCID**

Eldon Loh http://orcid.org/0000-0001-5063-4827

**References**

1. The big business of chronic pain treatment in Ontario: inside the Star investigation of pain doctors and injections. thestar.com; 2020. https://www.thestar.com/podcasts/thismatters/2020/10/08/the-big-business-of-chronic-pain-treatment-in-ontario-inside-the-star-investigation-of-pain-doctors-and-injections.html.

2. Batra RK, Krishnan K, Agarwal A. Paravertebral block. J Anaesthesiol Clin Pharmacol. 2011;27:5–11.

3. Richardson J, Lönqvist PA, Naja Z. Bilateral thoracic paravertebral block: potential and practice. BJ Anesth. 2011;106:164–71. doi:10.1093/bja/aeq378.

4. Iwata M, Kimoto K, Akasaki Y, Morioka M, Nakayama K, Matsuzawa N, Kuzumoto N, Shimomura T. [Unilateral thoracic paravertebral block for effective control of pain: a case report of a patient with esophageal cancer and cirrhosis of the liver.]. Masui. 2016;65:832–34.

5. Karmakar MK, Ho AM-H. Acute pain management of patients with multiple fractured ribs. J Trauma. 2003;54:615–25. doi:10.1097/00005397-200303000-00008.

6. Karmakar MK, Critchley LAH, Ho AMH, Gin T, Lee TW, Yim APC. Continuous thoracic paravertebral infusion of bupivacaine for pain management in patients with multiple fractured ribs. Chest. 2003;123(2):424–31. doi:10.1378/chest.123.2.424.

7. Veselis RA. Sedation and pain management for the critically ill. Crit Care Clin. 1988;4:167–81. doi:10.1016/S0749-0704(18)30510-4.

8. Beyaz SG, Özocak H, Ergönenç T, Erdem AF. The thoracic paravertebral block performed for open cholecystectomy operation in order to anesthesia: two cases. Anaesth Essays Res. 2014;8:239–42. doi:10.4103/0259-1162.134521.

9. Gupta K, Srikanth K, Girdhar KK, Chan V. Analgesic efficacy of ultrasound-guided paravertebral block versus serratus plane block for modified radical mastectomy: a randomised, controlled trial. Indian J Anaesth. 2017;61:381–86. doi:10.4103/jia.IJA_62_17.

10. Abo-Zeid MA, Elgamal MM, Hewidy AA, Moawad AA, Adel Elmaddawy AE. Ultrasound-guided multilevel paravertebral block versus local anesthesia for medical thoracoscopy. Saudi J Anaesth. 2017;11(4):442–48. doi:10.4103/sja.SJA_292_17.

11. Abu Elayed MM, Abdullah MA. Thoracic paravertebral block for the anesthetic management of percutaneous radiofrequency ablation of liver tumors. J Anaesthesiol Clin Pharmacol. 2018;34:166–71. doi:10.4103/joacp.JOACP_39_17.

12. Tighe SQM, Greene MD, Rajadurai N. Paravertebral block. Contin Educ Anaesth Crit Care Pain. 2010;10:133–37. doi:10.1093/bjaceaccp/mkq029.

13. Purcell-Jones G, Pither CE, Justins DM. Paravertebral somatic nerve block: a clinical, radiographic, and computed tomographic study in chronic pain patients. Anaesth Analg. 1989;68:32–39. doi:10.1213/00000539-198901000-00008.

14. Naja Z, Lönqvist PA. Somatic paravertebral nerve blockade. Incidence of failed block and complications. Anaesthesia. 2001;56:1184–88. doi:10.1046/j.1365-2044.2001.02084.x.
15. Pace MM, Sharma B, Anderson-Dam J, Fleischmann K, Warren L, Stefanovich P. Ultrasound-guided thoracic paravertebral blockade: a retrospective study of the incidence of complications. Anesth Analg. 2016;122:1186–91. doi:10.1213/ANE000000000001117.

16. American Society of Anesthesiologists Task Force on Chronic Pain Management & American Society of Regional Anesthesia and Pain Medicine. Practice guidelines for chronic pain management: an updated report by the American Society of anesthesiologists task force on chronic pain management and the American Society of regional anesthesia and pain medicine. Anesthesiology. 2010;112(4):810–33. doi:10.1097/ALN.0b013e3181c43103.

17. Jacobs H, Weinberg J, O’Con nell JS, Buckley N, Nussbaum D, Ko GD. Local anesthetic nerve blocks show improved quality of life. A population cross-sectional study in a community practice. Pract Pain Manage. 2019;19(5):31-36. https://www.practicalpainmanagement.com/treatments/interventional/injections/nerve-blocks-lead-improved-quality-life

18. Chronic pain patients praise nerve blocks for freeing them from the shackles of pain. thestar.com; 2020. https://www.thestar.com/news/investigations/2020/09/28/chronic-pain-patients-praise-nerve-blocks-for-freeing-them-from-the-shackles-of-pain.html.

19. “That’s an injection mill.” Ontario’s top-billing pain doctors capitalize on province’s lax rules, running up the public’s tab for chronic pain management. thestar.com; 2020. https://www.thestar.com/news/investigations/2020/09/28/that’s-an-injection-mill-ontarios-top-billing-pain-doctors-capitalize-on-provinces-lax-rules-running-up-the-publics-tab-for-chronic-pain-management.html

20. Loh E, Reid JN, Alibrahim F, Welk B. Retrospective cohort study of healthcare utilization and opioid use following radiofrequency ablation for chronic axial spine pain in Ontario, Canada. Reg Anesth Pain Med. 2019;44(3):398–405. doi:10.1136/rapm-2018-100058.

21. Raina P, Torrance-Rynard V, Wong M, Woodward C. Agreement between self-reported and routinely collected health-care utilization data among seniors. Health Serv Res. 2002;37(3):751–74. doi:10.1111/1475-6773.00047.

22. Williams J, Young W. A summary of studies of the quality of health care administrative databases in Canada. Patterns of health care in Ontario: the ICES practice atlas. 2nd ed. Can Med Assoc. 1996;339:45.

23. Gibson D, Richards H, Chapman A. The national ambulatory care reporting system: factors that affect the quality of its emergency data. Int J Inf Qual. 2008;2:97.

24. Levy AR, O’Brien BJ, Sellors C, Grootendorst P, Willison D. Coding accuracy of administrative drug claims in the Ontario Drug Benefit database. Can J Clin Pharmacol J Can Pharmacol Clin. 2003;10:67–71.

25. Iha P, Deboer D, Sykora K, David Naylor C. Characteristics and mortality outcomes of thrombolysis trial participants and nonparticipants: a population-based comparison. JACC. 1996;27(6):1335–42. doi:10.1016/0735-1097(96)00018-6.

26. Christensen LA. Introduction to building a linear regression model. In Proceedings of the Twenty-Second Annual SAS Users Group International Conference, San Diego, California; 1997.

27. Gaskin DJ, Richard P. The economic costs of pain in the United States. J Pain Off J Am Pain Soc. 2012;13(8):715–24. doi:10.1097/JPAI.0b013e31825ba27f.

28. Breivik H, Collett B, Ventafridda V, Cohen R, Gallacher D. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain. 2006;10(4):287–333. doi:10.1016/j.ejpa.2005.06.009.

29. Phillips CJ. The cost and burden of chronic pain. Rev Pain. 2009;3:2–5. doi:10.1177/204946370900300102.

30. Scott NA, Guo B, Barton PM, Gerwin RD. Trigger point injections for chronic non-malignant musculoskeletal pain: a systematic review. Pain Med Malden Mass. 2009;10:54–69. doi:10.1111/j.1526-4637.2008.00526.x.

31. Burger M, Africa C, Droomer K, Norman A, Pheiffe C, Gercke A, Samsodien A, Miszewski N. Effect of corticosteroid injections versus physiotherapy on pain, shoulder range of motion and shoulder function in patients with subacromial impingement syndrome: a systematic review and meta-analysis. South Afr J Physiother. 2016;72(1):318.

32. Van Der Sande R, Rinkel WD, Gebremariam L, Hay EM, Koes BW, Huisstede BM. Subacromial impingement syndrome: effectiveness of pharmaceutical interventions-nonsteroidal anti-inflammatory drugs, corticosteroid, or other injections; a systematic review. Arch Phys Med Rehabil. 2013;94:961–76. doi:10.1016/j.apmr.2012.11.041.

33. Lustenberger DP, Ng YY, Best TM, Ellis TJ. Efficacy of treatment of trochanteric bursitis: a systematic review. Clin J Sport Med Off J Can Acad Sport Med. 2011;21:447–53. doi:10.1097/JSM.0b013e318221299c.

34. Yen TC, et al. The effect of pain relief on daily physical activity: in-home objective physical activity assessment in chronic low back pain patients after paravertebral spinal block. Sens Switz. 2018;18(9):3048. doi:10.3390/s18093048.

35. Toosizadeh N, Harati H, Yen TC, Fastie C, Mohler J, Najaﬁ B, Dohm M. Paravertebral spinal injection for the treatment of patients with degenerative facet osteoarthritis; evidence of motor performance improvements based on objective assessments. Clin Biomech Bristol Avon. 2016;39:100–8. doi:10.1016/j.clinbiomech.2016.10.007.

36. MacVicar J, Borowczyk JM, MacVicar AM, Lougahan BM, Bogduk N. Lumbar medial branch radiofrequency neurotomy in New Zealand. Pain Med Malden Mass. 2013;14:639–45. doi:10.1111/pme.12000.

37. MacVicar J, Borowczyk JM, MacVicar AM, Lougahan BM, Bogduk N. Cervical medial branch radiofrequency neurotomy in New Zealand. Pain Med Malden Mass. 2012;13:647–54. doi:10.1111/j.1526-4637.2012.01351.x.

38. McDonald GJ, Lord SM, Bogduk N. Long-term follow-up of patients treated with cervical radiofrequency neurotomy for chronic neck pain. Neurosurgery. 1999;45:61–67. discussion 67–68. doi:10.1093/00006123-19990700-00015.